The purpose of this study is to learn more about late-onset epilepsy of unknown etiology (LOEU), which is defined as an onset of seizure activity in late life (age 60 or above) without a clear neurological cause. That is, many older adults will experience seizures due to neurological conditions such as stroke, brain injury, tumor, or infection. However, other individuals will also develop seizures with no identified cause.

Participation entails a single study visit lasting 2-3 hours including a fasting blood draw, completion of standardized cognitive testing, and several questionnaires. The goals of the study include to examine blood markers that can help us to better understand the condition including dementia risk, and how these markers may impact the clinical presentation of the condition. No interventions/treatments are included with this study.

We are testing a 2D system designed to help people with Parkinson's disease practice their speech. In this study, participants will speak with a virtual character, called an embodied conversational agent, using a laptop. Our goal is to see if this technology is helpful and easy to use for people with Parkinson's disease to use. This research will help us learn whether using virtual characters at home could support long-term speech improvements.

The purpose of this research study is to investigate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with computerized cognitive training might help improve thinking abilities and mood. Participants will self-administer these two treatments in their homes (two 1-hour session/day for 10 days). They will undergo pre- and post-treatment assessments of thinking abilities and mood and a brain MRI.

Hearing loss is common, but many people don't realize they have it until years after it begins. This study will explore whether everyday speech and conversation can reveal early signs of hearing loss. In one part of the study, we will record conversations between participants and healthcare professionals to study how speech patterns may differ in people with and without hearing loss. In another part, we will review transcripts from past clinic visits to see if certain patterns, like pauses or asking for things to be repeated, are linked to hearing problems. The goal is to develop tools that can help identify hearing loss earlier and more easily, using conversations that happen naturally during clinic visits.

Depression is common among cancer survivors, but current ways to address this area of care are lacking. In this project, we will work with cancer survivors and oncology providers to build a text-message based approach to screen cancer survivors for depression. Long term, we hope this research can be used to improve screening for depression for cancer survivors

This study will examine genetic factors that contribute to the different ways people feel after consuming cannabis. People that use cannabis at least 4 days per week will participate in a study involving 1 in-person visit followed by a 5-day remote assessment period. The in-person visit will determine if an individual is eligible for study participation and their blood will be drawn to assess genetics. During the remote assessment period, participants will complete multiple short surveys per day describing their feelings and their recent cannabis use.

The purpose of the study is to evaluate the safety and how well the medication sotatercept works versus placebo in treating Heart Failure with a Preserved Ejection Fraction. The study will also look at information obtained from the tests performed as part of the study to see if subjects have improvement in symptoms of heart failure. Participation in this study will last approximately 26 months. During the study period subjects will be asked to attend regular study visits with the research coordinator. These visits will include such activities as blood tests, questionnaires, physical evaluation by a study doctor, a right heart catheterization with exercise, echocardiogram, and 6 minute hall walks. There will be 35 visits as part of participation in this clinical trial.

Participants will be randomized to either the treatment group (and receive the medication) or the control group (and not receive the medication). Subjects will have a 2:1 chance of receiving the study medication during their participation in the trial. The treatment assignment is determined by randomization, where a computer selects at random which treatment group you will be in (like drawing straws). Neither the subject, nor the blinded personnel will know which group subjects are in. Neither the subject nor the study doctor will decide what group subjects are assigned. Participants from the placebo group in CADENCE who enter HARMONIZE at Visit 9a will be randomized 1:1 to one of the active treatment groups. Participants from an active treatment group in CADENCE entering HARMONIZE after Visit 9a will be allocated to continue in the same treatment group (ie, sotatercept dose level) as in CADENCE.

Profound racial inequities in statin use and cholesterol control mirror racial disparities in prostate cancer, where Black men are less likely to use a statin and have worse cholesterol control, are 78% more likely to be diagnosed with prostate cancer, and twice as likely to die from the disease compared to White men. Despite these parallels, the role of cholesterol control in prostate cancer racial disparities is poorly understood. Here, we investigate whether inequities in cholesterol control between Black and White men not using statins compared to cholesterol control in statin users contribute to prostate cancer racial disparities through interactions with tumor metabolism and the tumor microenvironment (TME), a novel concept supported by strong rationale.

The proposed research will qualitatively examine adolescent perspectives on adapting Written Exposure Therapy (WET), an evidence-based treatment for posttraumatic stress disorder (PTSD) among adults, for use with adolescents. The present study will take the first step in adapting WET for adolescents by conducting interviews with adolescents with PTSD. Interview questions will focus on identifying perceptions of WET and recommendations for adapting WET for the needs of adolescents. A brief survey will also be conducted. Participation in the interview and survey will involve a one-time study visit that lasts up to 60 minutes and can be conducted in person or virtually. Adolescent participants need be accompanied by a caregiver either in person or virtually.

This study is for patients that have been diagnosed with ovarian cancer who are taking bevacizumab. This study is testing two investigational drugs called nelfinavir and hydroxychloroquine. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA) for the treatment of cancer. The primary purpose of this study is to see if these two medications in combination with bevacizumab are safe and effective in ovarian cancer. These drugs will be given by mouth. Participants in this study can expect to be in this study for 6 months for data collection, but may continue on the study medications longer if seeing benefit.